have completed the divestment of Global Therapeautics to McPherson’s.
A Business Sale Agreement was announced on the 27th October.
Blackmores Chief Executive Officer Alastair Symington said, “We expect Global Therapeutics will flourish as a key business within McPherson’s Health Division.
Shares in Blackmores (ASX:BKL)
closed 1.01 per cent lower at $79.19 yesterday.